Based on this mechanism, a fusion peptide named PD-LYSO—comprising the PD-L1-binding domain (Q776–Q807) and the lysosomal sorting signal (M966–Q979) of HIP1R—has been designed to efficiently reduce PD-L1 expression in tumor cells [28]. This evidence concerns the gene HIP1R and neoplasm.